Cardiff Oncology Sets June ASCO Data Reveal as CRDF Stock Test Nears
Cardiff Oncology will present updated Phase 2 data for its onvansertib trial in metastatic colorectal cancer at ASCO on June 2, followed by a June 3 investor webcast. Shares closed at $1.78, down 0.6%. The company plans to advance to a Phase 3 trial, having aligned with the FDA on key design elements and selected the 30 mg dose for the next study.